Last reviewed · How we verify
Romosozumab and Denosumab Cycle Therapy
Romosozumab and denosumab work sequentially to first stimulate bone formation and then inhibit bone resorption, increasing bone mineral density in osteoporosis.
Romosozumab and denosumab work sequentially to first stimulate bone formation and then inhibit bone resorption, increasing bone mineral density in osteoporosis. Used for Osteoporosis in postmenopausal women at high risk of fracture.
At a glance
| Generic name | Romosozumab and Denosumab Cycle Therapy |
|---|---|
| Also known as | Cycle therapy group |
| Sponsor | National Taiwan University Hospital |
| Drug class | Bone-forming agent and antiresorptive agent combination therapy |
| Target | Sclerostin (romosozumab); RANKL (denosumab) |
| Modality | Small molecule |
| Therapeutic area | Bone metabolism / Osteoporosis |
| Phase | FDA-approved |
Mechanism of action
Romosozumab is a sclerostin inhibitor that promotes osteoblast activity and bone formation, while denosumab is a RANKL inhibitor that suppresses osteoclast-mediated bone resorption. The sequential or cyclic administration of these agents leverages their complementary mechanisms to achieve greater improvements in bone density and strength compared to monotherapy.
Approved indications
- Osteoporosis in postmenopausal women at high risk of fracture
Common side effects
- Injection site reactions
- Arthralgia
- Headache
- Hypocalcemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: